KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation

Transplantation

Volumn 84, Issue 8, 2007, Pages 1045-1051

  Kreijveld, Ellen ^a   Van Der Meer, Arnold ^a   Tijssen, Henk J ^a   Hilbrands, Luuk B ^a   Joosten, Irma ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute rejection; Killer cell immunoglobulin receptors; Natural killer cell; Reduction immunosuppression; Renal transplantation

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR LIGAND; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPEATED DRUG DOSE;

ADULT; EPITOPES; FEMALE; GRAFT REJECTION; HAPLOTYPES; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; LIGANDS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, KIR;

EID: 37349004768     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000286097.11173.70     Document Type: Article

References (40)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
2. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
3. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365.
4. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 2002; 74: 1725.
5. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
6. Bestard O, Cruzado JM, Grinyo JM. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 2005; 37: 3729.
7. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567.
8. Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64: 1027.
9. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes: Biology, development, and function. Cancer Immunol Immunother 2004; 53: 176.
10. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: Coordinated stimulation of innate and adaptive immunity. J Exp Med 2005; 202: 203.
11. Ciccone E, Pende D, Viale O, et al. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: Definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992; 175: 709.
12. Parham P, McQueen KL. Alloreactive killer cells: Hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003; 3: 108.
13. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995; 268: 405.
14. Wagtmann N, Rajagopalan S, Winter CC, et al. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 1995; 3: 801.
15. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997; 7: 739.
16. Colonna M, Brooks EG, Falco M, et al. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993; 260: 1121.
17. Karre K. Immunology. A perfect mismatch. Science 2002; 295: 2029.
18. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878.
19. Ruggeri L, Mancusi A, Burchielli E, et al. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 2007; 19: 142.
20. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633.
21. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: A potential new link between adaptive and innate immunity. Blood 2003; 101: 3052.
22. Ferlazzo G, Thomas D, Lin SL, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172: 1455.
23. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004; 172: 1333.
24. ter Meulen CG, van RI, Hene RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: A prospective, randomized, multicenter study. Am J Transplant 2004; 4: 803.
25. Gagne K, Brizard G, Gueglio B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271.
26. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11: 116.
27. Uhrberg M, Parham P, Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 2002; 54: 221.
28. Bontadini A, Testi M, Cuccia M, et al. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population. J Transl Med 2006; 4: 44.
29. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7: 753.
30. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644.
31. Bishara A, Brautbar C, Zamir G, et al. Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome. Hum Immunol 2005; 66: 1099.
32. Tran TH, Mytilineos J, Scherer S, et al. Analysis of KIR ligand incompatibility in human renal transplantation. Transplantation 2005; 80: 1121.
33. Vampa ML, Norman PJ, Burnapp L, et al. Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch. Transplantation 2003; 76: 1220.
34. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097.
35. van Besouw NM, van der Mast BJ, de KP, et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000; 70: 136.
36. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333.
37. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 2004; 173: 3653.
38. Dragun D, Hoff U, Park JK, et al. Prolonged cold preservation augments vascular injury independent of renal transplant immunogenicity and function. Kidney Int 2001; 60: 1173.
39. Yu G, Xu X, Vu MD, et al. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 2006; 203: 1851.
40. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155: 31.